Envista Holdings Corp Dossier
Qualitative Analysis
Business overview
Envista Holdings Corporation is a leading global dental products company that develops, manufactures, and markets a comprehensive portfolio of dental consumables, equipment, and services. Spun off from Danaher Corporation in 2019, the company operates through two primary business segments: Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment focuses on dental implants, regenerative solutions, dental prosthetics, and orthodontic bracket systems, aligners, and treatment software under premium brands such as Nobel Biocare, Ormco, and Spark. The Equipment & Consumables segment provides digital imaging systems, software, endodontic systems, restorative materials, and infection prevention products under brands like Dexis, Kerr, and CaviWipes. Envista serves dental professionals, clinics, and hospitals globally, with a strong presence in North America, Western Europe, and emerging markets.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Continuous improvement framework focused on lean manufacturing, commercial execution, and innovation leadership.
Expected impact: Drives productivity, supports gross margin expansion, and optimizes the overall cost structure.
Accelerating the commercial rollout of Spark clear aligners into new international markets, including the recent launch in Japan with StageRx technology.
Expected impact: Captures market share in high-growth aesthetic dentistry segments and improves segment profitability.
Enhancing the DEXIS software suite with FDA-cleared artificial intelligence capabilities for automated treatment planning and diagnostics.
Expected impact: Differentiates Envista's digital imaging ecosystem and anchors clinical workflows to drive hardware and software cross-selling.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the creator of the Denah Bur technology and pioneer of osseodensification. Unlike traditional drilling, osseodensification compacts bone to improve primary stability and shorten 'time to teeth'.
Financial impact: Contributed $4 million to Q1 2026 revenue. Expected to be accretive to Envista's overall growth, operating margins, EPS, and valuation multiples.
Strategic Partnerships
Selected to support Envista's digital transformation, IT infrastructure upgrades, and digital workflow solutions [3.4.1].
Terms: Not publicly disclosed